Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)

NCT01998893 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01998893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01998893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
January 31, 1997
Completion date
February 29, 2008
Enrollment
38 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma